Verastem Oncology (VSTM) Tops Q2 EPS by 12c
Tweet
Share
E-mailGet Alerts VSTM Hot Sheet
Join SI Premium – FREE
Verastem Oncology (NASDAQ: VSTM) reported Q2 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $40.07 million versus the consensus estimate of $23.09 million.
For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- Artiva Biotherapeutics, Inc. (ARTV) Misses Q2 EPS by 63c
- Soligenix, Inc. (SNGX) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
